Vertex Pharmaceuticals Incorporated
US ˙ NasdaqGS ˙ US92532F1003

SecurityVRTX / Vertex Pharmaceuticals Incorporated
InstitutionSWS Partners
Latest Disclosed Ownership2,573 shares
Latest Disclosed Value $ 1,148,726
SWS Partners reports 1.66% increase in ownership of VRTX / Vertex Pharmaceuticals Incorporated

On April 21, 2026 - SWS Partners filed a 13F-HR form disclosing ownership of 2,573 shares of Vertex Pharmaceuticals Incorporated (US:VRTX) valued at $1,148,947 USD as of March 31, 2026. The entity filed a previous 13F-HR on January 16, 2026 disclosing 2,531 shares of Vertex Pharmaceuticals Incorporated. This represents a change in shares of 1.66% during the quarter. The current value of the position is $1,102,119 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-04-21 2026-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 2,573 42 1.66 1,149 0.09 0.2833
2026-01-16 2025-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 2,531 13 0.52 1,148 16.45 0.2770
2025-10-16 2025-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 2,518 36 1.45 986 -10.86 0.2407
2025-07-17 2025-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 2,482 -785 -24.03 1,105 -15.97 0.2982
2025-05-19 2025-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 3,267 0 0.00 1,316 0.00 0.3984
2025-02-06 2024-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 3,267 20 0.62 1,316 -12.91 0.3984
2024-10-15 2024-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 3,247 -362 -10.03 1,510 -10.70 0.4810
2024-07-17 2024-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 3,609 -737 -16.96 1,692 -6.88 0.5057
2024-04-30 2024-03-31 13F Vertex Pharmaceutica VRTX-US 92532F100 4,346 -56 -1.27 1,817 1.40 0.5432
2024-02-13 2023-12-31 13F Vertex Pharmaceutica VRTX-US 92532F100 4,402 -72 -1.61 1,791 15.18 0.5838
2023-11-09 2023-09-30 13F Vertex Pharmaceutica VRTX-US 92532F100 4,474 -1,114 -19.94 1,556 -20.82 0.5751
2023-08-17 2023-06-30 13F/A-2 Vertex Pharmaceutica COM 92532F100 5,588 -60 -1.06 1,964 10.40 0.7085
2023-07-26 2023-06-30 13F Vertex Pharmaceutica COM 92532F100 5,588 -60 1,964 0.7047
2023-05-09 2023-03-31 13F Vertex Pharmaceutica COM 92532F100 5,648 5,648 1,780 0.6625
2023-01-30 2022-12-31 13F Vertex Pharmaceutica COM 92532F100 0 -5,592 -100.00 0 -100.00
2022-11-09 2022-09-30 13F Vertex Pharmaceutica COM 92532F100 5,592 28 0.50 1,619 3.25 0.7500
2022-07-28 2022-06-30 13F Vertex Pharmaceutica COM 92532F100 5,564 11 0.20 1,568 8.36 1.3200
2022-05-05 2022-03-31 13F Vertex Pharmaceutica COM 92532F100 5,553 -4,304 -43.66 1,447 -33.16 0.9464
2022-01-25 2021-12-31 13F Vertex Pharmaceutica COM 92532F100 9,857 2,508 34.13 2,165 62.42 1.2311
2021-11-08 2021-09-30 13F Vertex Pharmaceutica COM 92532F100 7,349 135 1.87 1,333 -8.38 0.8259
2021-08-09 2021-06-30 13F Vertex Pharmaceutica COM 92532F100 7,214 140 1.98 1,455 -4.28 0.9469
2021-05-17 2021-03-31 13F Vertex Pharmaceutica COM 92532F100 7,074 3,289 86.90 1,520 69.83 1.0461
2021-03-31 2020-12-31 13F Vertex Pharmaceutica COM 92532F100 3,785 1,030 37.39 895 19.33 0.3988
2020-11-13 2020-09-30 13F Vertex Pharmaceutica COM 92532F100 2,755 299 12.17 750 12.28 0.3757
2020-08-13 2020-06-30 13F VERTEX PHARMACEUTICA COM 92532F100 2,456 261 11.89 668 27.97 0.8506
2020-05-14 2020-03-31 13F VERTEX PHARMACEUTICA COM 92532F100 2,195 582 36.08 522 54.90 0.3731
2019-11-21 2019-09-30 13F/A-1 VERTEX PHARMACEUTICA COM 92532F100 1,613 -178 -9.94 337 5.64 0.1995
2019-11-15 2019-09-30 13F VERTEX PHARMACEUTICA COM 92532F100 30,118 28,327 5,272 191,869.0050
2019-08-13 2019-06-30 13F VERTEX PHARMACEUTICA COM 92532F100 1,791 384 27.29 319 36.91 0.2026
2019-02-04 2018-12-31 13F VERTEX PHARMACEUTICA COM 92532F100 1,407 -132 -8.58 233 -21.55 0.1766
2018-11-14 2018-09-30 13F VERTEX PHARMACEUTICA COM 92532F100 1,539 1,539 297 0.1886
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.